Current strategies for CML treatment involve the use of tyrosine kinase inhibitors, which can inhibit the BCR-ABL phosphorylation, thereby preventing the proliferation of cancer cells and activating subsequent apoptosis [2, 6–9]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.